City of Hope Researchers Present Groundbreaking Cancer Treatment Approaches and Combinations at ASCO Annual Meeting

Strategic Insights -

At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, researchers from City of Hope are set to present novel cancer treatment approaches and combinations that could reduce cancer risk and improve survival. These breakthroughs include innovative combination therapies that target and shrink tumors once untouchable, identifying cancer biomarkers to determine best treatment options, and large, real-world data to guide cancer management.

Key Takeaways:

  • **Real-world data shows it is safe to readminister trastuzumab-deruxtecan to metastatic breast cancer patients who experience low-grade lung complications**: A multicenter retrospective study found that patients with asymptomatic grade 1 ILD after the resolution of imaging findings can be safely rechallenged with T-DXd. Among the patients rechallenged, 56% received steroids for a median of 36 days, and radiographic improvement was seen at a median of 24 days vs. 82 days for those who did not receive steroids.
  • **Tracking the genomic evolution of kidney cancer and recurrence to identify biomarkers of care**: A Phase 3 trial found that patients with specific genomic biomarkers in that Phase 3 trial experienced longer disease-free survival when atezolizumab was used after kidney resection. The researchers identified a genomic evolution in disease progression that offers insights into why patients with RCC relapse.
  • **A combination treatment of checkpoint inhibitors Vilastobart and atezolizumab shows promise in patients with advanced colorectal cancer**: A Phase 2 trial found that metastatic colorectal cancer patients with microsatellite stability (MSS) demonstrated initial evidence of anti-tumor activity when treated with the checkpoint inhibitors Vilastobart (XTX101) and atezolizumab. 27% of patients without liver metastatic disease experienced a partial response, defined as more than 50% shrinkage of target lesions.
  • **Using real-world data to provide insights into treatment that has a lower chance of causing heart attack and stroke in prostate cancer patients**: A study used real-world data to confirm clinical trial findings which suggest mCRPC patients who have never had chemotherapy and were treated with testosterone blocker abiraterone acetate have a higher risk of hospitalization due to cardiovascular events than patients treated with androgen receptor inhibitor enzalutamide.

Statistics:

  • A retrospective study of 712 metastatic breast cancer patients treated with T-DXd found that 56% received steroids for a median of 36 days, and radiographic improvement was seen at a median of 24 days vs. 82 days for those who did not receive steroids.
  • In a Phase 3 trial, patients with specific genomic biomarkers in that Phase 3 trial experienced longer disease-free survival when atezolizumab was used after kidney resection.
  • A Phase 2 trial found that 27% of patients without liver metastatic disease experienced a partial response, defined as more than 50% shrinkage of target lesions, when treated with Vilastobart (XTX101) and atezolizumab.
  • A study of more than 68 million seniors who are U.S. Medicare and Medicaid beneficiaries found that mCRPC patients who were 65 or older and have never had chemotherapy and were treated with abiraterone acetate had a statistically significant higher risk of experiencing cardiovascular events like heart attacks, strokes, coronary revascularization to restore blood flow, heart failure, irregular heart rhythm and blood clots compared to mCRPC patients treated with enzalutamide.

Sources:

  • BusinessWire.com: "City of Hope Researchers Present Groundbreaking Cancer Treatment Approaches and Combinations at ASCO Annual Meeting"
  • ASCO Annual Meeting Abstracts:

+ 1015: Real-world data show it is safe to readminister trastuzumab-deruxtecan to metastatic breast cancer patients who experience low-grade lung complications

+ 4510: Tracking the genomic evolution of kidney cancer and recurrence to identify biomarkers of care

+ 3553: A combination treatment of checkpoint inhibitors Vilastobart and atezolizumab shows promise in patients with advanced colorectal cancer

+ 5041: Using real-world data to provide insights into treatment that has a lower chance of causing heart attack and stroke in prostate cancer patients